LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

Home・Lista de Ações・Fate Therapeutics Inc

Fate Therapeutics Inc

Fechado

SetorSaúde

2.35 54.61

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.51

Máximo

1.58

Indicadores-chave
By Trading Economics
Rendimento	-124K -32M
Vendas	-372K 1.4M
EPS	-0.27
Margem de lucro	-2,364.792
Funcionários	161
EBITDA	-13M -42M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+150% upside

Dividendos
By Dow Jones
Próximos Ganhos	11 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-22M 152M
Abertura anterior	-52.26
Fecho anterior	2.35

Sentimento de Notícias

By Acuity

33%

67%

126 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.9101 / 1.14 Suporte e Resistência

Fate Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de mai. de 2026, 23:43 UTC

Notícias Principais

New Zealand's Unemployment Rate Falls in 1Q

5 de mai. de 2026, 23:20 UTC

Ações em Alta

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 de mai. de 2026, 21:48 UTC

Ganhos

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 de mai. de 2026, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 de mai. de 2026, 00:00 UTC

Conversa de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 de mai. de 2026, 22:26 UTC

Conversa de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 de mai. de 2026, 22:20 UTC

Conversa de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 de mai. de 2026, 22:08 UTC

Ganhos

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 de mai. de 2026, 22:07 UTC

Ganhos

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Rev $1.2B >PAAS

5 de mai. de 2026, 21:42 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:38 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:30 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:29 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:26 UTC

Ganhos

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q EPS 39c >ALC.EB

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 de mai. de 2026, 21:24 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:18 UTC

Ganhos

Mistras Backs 2026 Rev $730M-$750M >MG

5 de mai. de 2026, 21:17 UTC

Ganhos

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 de mai. de 2026, 21:15 UTC

Ganhos

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 de mai. de 2026, 21:12 UTC

Ganhos

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 de mai. de 2026, 21:11 UTC

Ganhos

SSR Mining 1Q Rev $581.8M >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q EPS $1.16 >SSRM

5 de mai. de 2026, 21:08 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:01 UTC

Ganhos

Intact Financial 1Q EPS C$4.12 >IFC.T

5 de mai. de 2026, 21:01 UTC

Ações em Alta

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparação entre Pares

Variação de preço

Fate Therapeutics Inc Previsão

Preço-alvo

By TipRanks

150% parte superior

Previsão para 12 meses

Média 4.5 USD 150%

Máximo 7 USD

Mínimo 2 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Fate Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Fate Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.9101 / 1.14Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentimento

By Acuity

126 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.